This study will examine the efficacy of the medication gemfibrozil in reducing alcohol consumption in individuals with an alcohol use disorder who are seeking treatment for alcohol-related problems. Twenty individuals will be randomized to receive four weeks of either gemfibrozil or placebo and retrospective reports of alcohol use will be collected throughout the trial. In addition, brain imaging measures will be collected at baseline and after two weeks of treatment to determine the effects of gemfibrozil on brain functioning.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
3
Gemfibrozil capsules (600 mg) taken twice per day
Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
The Mind Research Network
Albuquerque, New Mexico, United States
Mean Standard Drinks Per Drinking Day
Average number of standard drinks consumed on drinking days
Time frame: Baseline
Mean Standard Drinks Per Drinking Day
Average number of standard drinks consumed on drinking days
Time frame: 2 weeks post baseline
Mean Standard Drinks Per Drinking Day
Average number of standard drinks consumed on drinking days
Time frame: 4 weeks post baseline
Percent Days Abstinent
Percentage of days of abstinence from alcohol
Time frame: Baseline
Percent Days Abstinent
Percentage of days of abstinence from alcohol
Time frame: 2 weeks post baseline
Percent Days Abstinent
Percentage of days of abstinence from alcohol
Time frame: 4 weeks post baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.